0001544927-21-000003.txt : 20210617 0001544927-21-000003.hdr.sgml : 20210617 20210617141459 ACCESSION NUMBER: 0001544927-21-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20210617 DATE AS OF CHANGE: 20210617 EFFECTIVENESS DATE: 20210617 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alcyone Therapeutics, Inc. CENTRAL INDEX KEY: 0001544927 IRS NUMBER: 274036551 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-403333 FILM NUMBER: 211024296 BUSINESS ADDRESS: STREET 1: 250 JACKSON STREET STREET 2: UNIT 494, MILL NO. 5 BUILDING CITY: LOWELL STATE: MA ZIP: 01852 BUSINESS PHONE: 781-929-6094 MAIL ADDRESS: STREET 1: 250 JACKSON STREET STREET 2: UNIT 494, MILL NO. 5 BUILDING CITY: LOWELL STATE: MA ZIP: 01852 FORMER COMPANY: FORMER CONFORMED NAME: Alcyone Lifesciences, Inc. DATE OF NAME CHANGE: 20120315 D 1 primary_doc.xml X0708 D LIVE 0001544927 Alcyone Therapeutics, Inc. 116 John Street #300, Boott Mills South LOWELL MA MASSACHUSETTS 01852 978-709-1946 DELAWARE Alcyone Lifesciences, Inc. Corporation true PJ Anand c/o ALCYONE THERAPEUTICS, INC. 116 John Street #300, Boott Mills South LOWELL MA MASSACHUSETTS 01852 Executive Officer Director Richard Upton c/o ALCYONE THERAPEUTICS, INC. 116 John Street #300, Boott Mills South LOWELL MA MASSACHUSETTS 01852 Director Edgar Jannotta, Jr. c/o ALCYONE THERAPEUTICS, INC. 116 John Street #300, Boott Mills South LOWELL MA MASSACHUSETTS 01852 Director David Donabedian c/o ALCYONE THERAPEUTICS, INC. 116 John Street #300, Boott Mills South LOWELL MA MASSACHUSETTS 01852 Director Cameron Durrant c/o ALCYONE THERAPEUTICS, INC. 116 John Street #300, Boott Mills South LOWELL MA MASSACHUSETTS 01852 Director Stephen Oesterle c/o ALCYONE THERAPEUTICS, INC. 116 John Street #300, Boott Mills South LOWELL MA MASSACHUSETTS 01852 Director Piratip Pratumsuwan c/o ALCYONE THERAPEUTICS, INC. 116 John Street #300, Boott Mills South LOWELL MA MASSACHUSETTS 01852 Director Mr. Pratumsuwan was elected as a Director after the Date of First Sale. Other Health Care Decline to Disclose 06b false 2021-06-08 false true false 0 37103349 37103349 0 Total Offering Amount and Total Amount Sold include $14,103,364.13 issuable upon cancellation and conversion of indebtedness. false 31 0 0 0 true false Alcyone Therapeutics, Inc. /s/ PJ Anand PJ Anand President and Chief Executive Officer 2021-06-17